Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-253 in advanced solid tumors
NCT05906862Phase 1Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Nov 2023
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AMT-253 in solid tumor (advanced stage), sponsored by Multitude Therapeutics. Primary endpoints: Recommended Phase 2 Dose up to 24 months, Maximum Tolerated Dose up to 24 months and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
AMT-253
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05906862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906862.